Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Fate Therapeutics Inc    FATE

FATE THERAPEUTICS INC (FATE)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Fate Therapeutics : and Memorial Sloan Kettering Cancer Center Expand Scope of License Agreement to include Gene-edited T-cell Immunotherapies

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2018 | 04:23pm CEST

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today the Company has gained access to additional intellectual property from Memorial Sloan Kettering Cancer Center (MSK) that enables the development of gene-edited T-cell immunotherapies. The newly-licensed portfolio of intellectual property covers new chimeric antigen receptor (CAR) constructs as well as off-the-shelf CAR T cells, including the use of CRISPR and other innovative technologies for their production.

Fate Therapeutics is utilizing gene editing under its ongoing collaboration for the research and development of off-the-shelf CAR T-cell immunotherapies with Michel Sadelain, M.D., Ph.D., Director of the Center for Cell Engineering and the Stephen and Barbara Friedman Chair at MSK. At the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting, Dr. Sadelain will present preclinical data on FT819, an off-the-shelf, TCR-less, CD19 CAR T-cell product manufactured from a clonal master induced pluripotent stem cell (iPSC) line.

"Engineering stem cells and using master iPSC lines for the renewable production of off-the-shelf CAR T cells has the potential to advance the cancer immunotherapy landscape," said Dr. Sadelain. "We are pleased with the breakthrough discoveries accomplished under our ongoing collaboration with Fate Therapeutics, and look forward to continuing our advancement together of off-the-shelf CAR T-cell products toward clinical development."

The use of clonal master iPSC lines can overcome the complexity, heterogeneity and substantial costs associated with using cells from a patient or an allogeneic donor. Instead, iPSC-derived T-cell immunotherapies can be consistently and repeatedly mass produced and delivered in an off-the-shelf manner, significantly reducing the cost of, and time to, patient treatment.

"The use of a gene-edited master iPSC line for the manufacture of off-the-shelf T-cell immunotherapies ensures complete removal of endogenous TCR expression, which is critical to avoid the life-threatening complication of graft-versus-host disease that is seen in allogeneic T-cell therapy," said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. "The incorporation of these latest MSK technologies into our development of FT819 and our iPSC product platform advances our leadership position in developing off-the-shelf T-cell immunotherapies with improved safety, enhanced potency and expanded therapeutic reach."

Fate Therapeutics has exclusively licensed from MSK intellectual property covering the production and composition of iPSC-derived T cells for human therapeutic use. In addition, Fate Therapeutics owns an extensive intellectual property portfolio that broadly covers compositions and methods for the genome editing of iPSCs using CRISPR and other nucleases, including the use of CRISPR to insert a CAR in the TRAC locus for endogenous transcriptional control.

(c) 2018 Future Publishing Limited Quay House, The Ambury, Bath BA1 1UA. All rights reserved Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on FATE THERAPEUTICS INC
08/14FATE THERAPEUTICS : to Present at the 2018 Wedbush PacGrow Healthcare Conference
AQ
08/10FATE THERAPEUTICS : Reports Second Quarter 2018 Financial Results and Highlights..
AQ
08/07Fate Therapeutics to Present at the 2018 Wedbush PacGrow Healthcare Conferenc..
GL
08/06FATE THERAPEUTICS : 2Q Earnings Snapshot
AQ
08/06FATE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition ..
AQ
08/06FATE THERAPEUTICS INC : Results of Operations and Financial Condition, Financial..
AQ
08/06Fate Therapeutics Reports Second Quarter 2018 Financial Results and Highlight..
GL
08/06FATE THERAPEUTICS INC : Fate Therapeutics, Inc. to Host Earnings Call
AC
08/02FATE THERAPEUTICS : to Webcast Conference Call Reporting Second Quarter 2018 Fin..
AQ
08/01FATE THERAPEUTICS INC : Change in Directors or Principal Officers, Other Events ..
AQ
More news
News from SeekingAlpha
08/06Fate Therapeutics, Inc. (FATE) CEO Scott Wolchko on Q2 2018 Results - Earning.. 
08/06Fate Therapeutics misses by $0.06, misses on revenue 
08/06Fate Therapeutics misses by $0.06, misses on revenue 
08/05Notable earnings after Monday?s close 
07/17Playing The Expectations Game In Biotech 
Financials ($)
Sales 2018 5,15 M
EBIT 2018 -65,5 M
Net income 2018 -66,1 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 116x
Capi. / Sales 2019 283x
Capitalization 598 M
Chart FATE THERAPEUTICS INC
Duration : Period :
Fate Therapeutics Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FATE THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 18,2 $
Spread / Average Target 62%
EPS Revisions
Managers
NameTitle
J. Scott Wolchko President, Chief Executive Officer & Director
William H. Rastetter Chairman
Daniel D. Shoemaker Chief Scientific Officer
Chris M. Storgard Chief Medical Officer
Amir H. Nashat Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
FATE THERAPEUTICS INC83.31%598
GILEAD SCIENCES1.79%94 529
VERTEX PHARMACEUTICALS16.75%44 999
REGENERON PHARMACEUTICALS-1.11%39 726
NEUROCRINE BIOSCIENCES, INC.46.41%10 370
GENMAB2.28%9 923